Advanced search
Advanced search
Advanced search
Advanced search
Advanced search
New drugs based on recombinant DNA technology
Komitet Biotechnologii PAN ; Instytut Chemii Bioorganicznej PAN
Over the last 20 years, some 100 biopharmaceuticals have gained marketing authorization in Europe, USA and other world regions. All biopharmaceu- tical products currently approved within the EU are protein-based. The majority of the first generation products were either unmodified monoclonal antibodies or proteins used clinically to either replace or augment levels of native human proteins. With the recent advances in genomics, proteomics, pharmaceutical target validation, and lead compound identification new perspectives of bio- pharmaceutical products development emerged. Protein engineering has recently facilitated the rational development of a number of proteins displaying an altered pharmacokinetics, biodistribution and therapeutic properties. New strategies and challenges in biopharmaceuticals developments yielded the second generation of protein drugs.
Biotechnologia, vol.66, 3 (2004)-.
0860-7796 ; oai:rcin.org.pl:119236
Biblioteka Instytutu Chemii Bioorganicznej PAN
Licencja Creative Commons Uznanie autorstwa-Na tych samych warunkach 4.0
Instytut Chemii Bioorganicznej Polskiej Akademii Nauk
Instytut Chemii Bioorganicznej Polskiej Akademii Nauk
Oct 2, 2020
Mar 30, 2020
1956
https://rcin.org.pl./publication/148484
Edition name | Date |
---|---|
Nowe leki otrzymywane przy udziale technologii rekombinowanego DNA | Oct 2, 2020 |
Godawska, Anna Kieć-Kononowicz, Katarzyna
Latacz, Gniewomir Pękala, Elżbieta Kieć-Kononowicz, Katarzyna
Godawska, Anna Pękala, Elżbieta Kieć-Kononowicz, Katarzyna
Borkowska, Bożenna
Ziółkowski, Piotr Babula- Skowrońska, Danuta Kaczmarek, Małgorzata Cieśla, Agata Sadowski, Jan
Nowak, Jacek K.